DelveInsight’s “Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Eosinophilic Esophagitis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Eosinophilic Esophagitis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Eosinophilic Esophagitis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Eosinophilic Esophagitis: An Overview
Eosinophilic Esophagitis (EoE) represents a chronic, local immune-mediated esophageal disease, characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. The disease is understood as a clinical-pathological entity, where symptoms and histology must always be considered together, both for the diagnosis and for the follow-up or assessment of the response to treatment.
Clinical manifestations in infants and toddlers generally include vomiting, food refusal, choking with meals, and less commonly, failure to thrive. Predominant symptoms in school-aged children and adolescents include dysphagia (difficulty swallowing), food impaction, and choking/gagging with meals, particularly while eating foods with coarse textures. Other symptoms in this patient population include abdominal/chest pain, vomiting, and regurgitation.
Eosinophilic Esophagitis Market Key Facts
-
The total diagnosed prevalent patient population of eosinophilic esophagitis (EoE) in the 7MM countries was more than 700,000 cases in 2021.
-
As per the National Organization of Rare Disorders (NORD), the frequency of eosinophilic esophagitis has been estimated to be approximately 1 in 2,000 individuals. This condition has been reported in multiple continents including Europe, and America.
-
The United States accounted for the highest number of cases in 7MM, 319,000+ cases in 2020 for EoE.
-
Several companies are working robustly on many new therapies, such as cendakimab (BMS), benralizumab (AstraZeneca), estrasimod (Pfizer), ESO-101 (ESOCAP), lirentelimab (Allakos), APT-1011 (Ellodi Pharmaceutical), and several others.
Eosinophilic Esophagitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Eosinophilic Esophagitis pipeline therapies. It also thoroughly assesses the Eosinophilic Esophagitis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Eosinophilic Esophagitis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Eosinophilic Esophagitis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Eosinophilic Esophagitis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Eosinophilic Esophagitis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Eosinophilic Esophagitis Epidemiology, Segmented as –
-
Diagnosed prevalent cases of Eosinophilic Esophagitis in the 7MM [2019–2032]
-
Gender-specific Prevalent Cases of Eosinophilic Esophagitis in the 7MM [2019–2032]
-
Age-specific Prevalent Cases of Eosinophilic Esophagitis in the 7MM [2019–2032]
Eosinophilic Esophagitis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Eosinophilic Esophagitis market or expected to be launched during the study period. The analysis covers the Eosinophilic Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Eosinophilic Esophagitis drugs based on their sale and market share.
The report also covers the Eosinophilic Esophagitis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Eosinophilic Esophagitis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Eosinophilic Esophagitis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market
Eosinophilic Esophagitis Therapeutics Analysis
Current Eosinophilic Esophagitis treatment includes the use of drugs or dietary modifications capable of inducing and maintaining remission of symptoms and esophageal eosinophilia infiltration and endoscopic dilation to resolve strictures or reduced caliber of the esophagus, as a consequence of the fibrotic remodeling process of the esophagus.
Several major pharma and biotech companies are developing the therapies for Eosinophilic Esophagitis. Currently, Ellodi Pharmaceuticals is leading the therapeutics market with its Eosinophilic Esophagitis drug candidates in the most advanced stage of clinical development.
Eosinophilic Esophagitis Companies Actively Working in the Therapeutics Market Include
-
Allakos
-
Aqilion
-
Arena Pharmaceuticals
-
AstraZeneca
-
Bristol Myers Squibb (BMS)
-
Calypso Biotech
-
DBV Technologies
-
Dr Falk Pharma
-
Ellodi Pharmaceuticals
-
EsoCap AG
-
GlaxoSmithKline
-
Kyowa Hakko Kirin
-
Landos Biopharma
-
Pfizer
-
Regeneron Pharmaceuticals
-
Revolo Biotherapeutics
-
Sanofi
-
Serpin Pharma
-
Takeda
And Many Others
Emerging and Marketed Eosinophilic Esophagitis Therapies Covered in the Report Include:
-
APT-1011: Ellodi Pharmaceuticals.
-
Benralizumab: AstraZeneca
-
Budesonide Oral Suspension: Takeda
-
Cendakimab: Bristol-Myers Squibb
-
Dupilumab: Regeneron Pharmaceuticals/Sanofi
-
ESO-101: EsoCap AG
-
Etrasimod: Arena Pharmaceutical
-
Lirentelimab: Allakos
-
Mepolizumab: GlaxoSmithKline
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Eosinophilic Esophagitis Competitive Intelligence Analysis
4. Eosinophilic Esophagitis Market Overview at a Glance
5. Eosinophilic Esophagitis Disease Background and Overview
6. Eosinophilic Esophagitis Patient Journey
7. Eosinophilic Esophagitis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Eosinophilic Esophagitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Eosinophilic Esophagitis Unmet Needs
10. Key Endpoints of Eosinophilic Esophagitis Treatment
11. Eosinophilic Esophagitis Marketed Therapies
12. Eosinophilic Esophagitis Emerging Drugs and Latest Therapeutic Advances
13. Eosinophilic Esophagitis Seven Major Market Analysis
14. Attribute Analysis
15. Eosinophilic Esophagitis Market Outlook (In US, EU5, and Japan)
16. Eosinophilic Esophagitis Companies Active in the Market
17. Eosinophilic Esophagitis Access and Reimbursement Overview
18. KOL Views on the Eosinophilic Esophagitis Market
19. Eosinophilic Esophagitis Market Drivers
20. Eosinophilic Esophagitis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Listeriosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Listeriosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Listeriosis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/